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ldlling and can be used to purge leukemic cells fi'om hematopoiet- 
ic stenr cell (HSC) products in an experimental nmrine transplan 
ration model. We now wish to extend our studies to examine the 
use of PS-341 administration post-HSC transplant. We hypothe- 
sized that PS-341 would reduce GVHD associated mortality by 
preventing degradation of IkB leading to decreased NF-kB DNA 
binding activity and NF-kB dependent cytokinc production. V~Ze 
tested tire efficacy of PS-341 administration i a full MHC mis- 
matched routine model of acute lethal GVHD. C57BL/6 bone 
marrow and splenocytes were transplanted into lethally irradiated 
BALB/c hosts. PS-341 (lmg/kg) was administered on the day of 
transplant and also at later time points in some groups. Under 
experimental conditions where animals that receive vehicle con- 
trol succumb to acute GVHD within 12 days of transplant, mice 
that received PS-34l on the day of transplant are protected from 
lethal disease (log rank test p< 0.0001). However, administration 
of PS-341 dur ing the first week post - t ransplant  resulted in 
markedly accelerated mortality due to GVHD.  These studies 
demonstrate that the proteasome inhibitor PS-341 can be given 
concurrent with allogeneic HSC transplantation and can reduce 
early lethal acute GVHD although timing of the administration is 
critical. 
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TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) RELAPS- 
ING AFTER MYELOABLATIVE STEM CELL TRANSPLANTATION WITH 
STI-571 (IMATINIB MESYLATE) WITH OR WITHOUT DONOR LYM- 
PHOCYTE INFUSION (DLI) 
Barrett, ~.A.; Battiz~ala, M.; Solm~lom S.; Cbilds, R.; Hem'el, ~ ;  TVebvleJl, 
L.; Kztrlamtet; R. Stezzt Cell AllogeJzeic Tl:allspla~itatioJl Sectio~, Helmztol- 
o W B*'aT~ch, NHLBI, NatiolTal h~stitutes ofHealtb, DHHS, Betbesda, MD. 
CML relapsing after allogencic stem cell transplantation (SCT) can 
be successfully retreated with DLI. However DLI can cause GVHD 
and is less effective for hematological relapse. We therefore used 
STI-571 to treat patients with CML relapsing after SCT following 
myelobalative preparative regimens. Ten patients (9 who had not 
received STI-571 pretransplant) relapsed 4-36 months post trans- 
plant. Five were molecular elapses, five were more advanced ( kary- 
otypic = 1, chronic phase (CP) = 2, blast crisis (BC) =2). STI-571 300- 
600 rag/day was given to all patients who had a minimum of two 
positive RT-PCR assays *2 months apart, or who developed hemato- 
logical relapse. Prior to treatment, immtmosuppression was stopped 
on all patients (n=9) without active GV~tD. STI as a single agent was 
given to 5 molecular eIapses. Two had failed prior DLI. Four 
patients prompdy became PCR negative within 6 weeks. However 
three had a molecular relapse after STI was stopped and are currently 
retreated. STI 571 combined with 1-5 xl07/kg CD3+ DLI was given 
to 5 patients relapsing with more advanced CML. Three (CP or kat T- 
otypic relapse) achieved complete molecular emissions, sustained in 
two. One myeloid BC patient developed extensive chronic GVHD 
after DLI given day 100 to treat persisting molecular disease, STI was 
stopped because of thrombocytopeuia, he progressed with chloromas 
by 5 months post-transplant but has achieved a stable molecular 
remission persisting >6 months after restarting STI 600rag/day. One 
patient relapsing in ALL BC achieved a hematological remission but 
relapsed again 3 months later and died of disease progTession.Thus, 
of I0 STI-txeated patients, 7achieved molecular remission which was 
sustained in 4. These results uggest hat the cytoreductive action of 
STI can synergize with the graft-versus-leukemia effect. However, 
the tendency for further elapse when STI is withdrawn suggests that 
cure of relapsed CML may also require a GVL effect. 
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INFUSION OF HIGH NUMBERS OF G-CSF MOBILIZED BLOOD DEN- 
DRITIC CELLS TYPE 2 (DC-2) IS ASSOCIATED WITH AN INCREASED 
RATE OF CHRONIC GVHD IN ALLOGENEIC PBSC TRANSPLANTATION 
Rm~delli, D2; Avpi~lati, M. 7, CtJi'J'zcmbolo, G.1; UvbiHi, B.~; BoJ~tzi, 
F J; Sm~zaJzi, M.t; Falcimzi, S.I; BmzdiJzi, G.~; Baccava~i, M. s 1. U~zi- 
ve'~'sit~ ofllli~zois at Chicago, Ste~zz Cell T~'mzspla~t P~'og~w~n, Cb#ago, 
IL; 2. U~zivers#y of Bohwza, Bolog~za, Italy. 
It was previously shown that dendritic cells type-2 (DC-2) are 
significantly increased in G-CSF-mobil ized leukapheresis prod- 
ucts as compared to unstimulated bone marrow. In this study, we 
analysed whether the numbers of DC-1 and DC-2, as well as of 
other cell components in the graft, was associated with acute 
and/or chronic GVI ID in 31 adult patients (11 MM, 7 CML CP, 
6 AML, 5 NHL,  and 2 MDS) receiving an allogeneic PBSC trans- 
plant from HLA-lnatched siblings. Average cell doses (xl06/kg) in 
the grafts were the following: 283_+137 CD3+ T ceils, 160_+88 
CD4+ T lymphocytes, 116_+55 CDS+ T lymphocytes, 64_+39 
CD19+ B lymphocytes, 51_+29 CD56+ NK cells, 253_+103 CD14+ 
monocytes, 6.6+4.1 CD34+ cells, 2.1_+0.9 HLA-DR+lin-CD i I c+ 
DC-1 and 2.9_+1.3 HLA-DR+lin-CD123+ DC-2. Median follow 
up was 255 days (range: 50-685). Patients were initially divided in 
three groups according to whether they had shown no signs of 
acute GVHD (grade 0, n=10), acute GVHD grade I (n=12), or 
grade II - IV (n=9). Median numbers of CD34+ cells, lymphocyte 
subsets, and DC-1 and DC-2 received by patients in these three 
groups did not differ significantly. Of 21 patients with adequate 
follow up (median 485 days, range: 131-695) 12 developed chronic 
GVHD (10 extensive, 2 limited). Analysis of cell components of 
the grafts demonstrated that patients developing chronic GVHD 
had received a signifcantly higher dose of DC-2 than patients 
without chronic GVHD (3.3+_1.5 vs 2.2_+0.9, p=0.05), while the 
dose of DC-1 (p=0.7), monocytes (p-0.28), T lymphocytes 
(p=0.643), B lymphocytes (p=0.939), NK  cells (p=0.487) and 
CD34+ cells (p=0.757) was not different. Also, chronic GVHD did 
not correlate with recipient or donor age or gender, interval 
between diagnosis and transplant, presence of ATG or TBI in the 
conditioning regimen, or type of GVHD prophylaxis. Our results 
suggest hat the presence of large DC-2 numbers in the graft may 
be associated with a higher risk of chronic GVHD after allogeneic 
PBSC transplantation. These data might prompt further studies 
addressing whether depletion of graft DC-2 might be beneficial in 
this setting. 
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SOLID TUMOR VACCINES ELICIT DISTINCT IMMUNE RESPONSES 
FROM HOST VERSUS DONOR T CELLS IN MIXED CHIMERAS CREATED 
BY NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTA- 
TION (NST) 
Dzll:atcovic, NJ; Slmzsk~ , ,7.E.e; Pmdoll, I).MS; Fucbs, E.J.1; Lt~zMk, 
LJ 1. The Sidemen, Ki71zTnel Cmz~p~'ehe~zsive Cm~ceT- Cez~te1" at ffohlzs Hop- 
kiJzs, Balti71zore, AJD; 2. Dept. of bz~'mztz~ology, UJziv. of Colo~wdo 
Health &'ieJzces CeJ~te~5 DeTzve~, CO. 
A growing body of evidence suggests that functional unrespon- 
siveness of the immune system to growing solid tumors may be 
due to tolerance in minor-specific CD4 + T cells, whereas tumor 
specific CD8 + T cells exist in a state of partial activation with lim- 
ited effector function. We therefore hypothesized that an allo- 
geneie graft-versus host reaction may provide a helper effect that 
augments the anti-tumor immune response of host CD8 + T cells 
in mixed henaatopoietic chimeras. To test this hypothesis, we ana- 
lyzed host versus donor T cell responses to AH1, an H-2L 'u- 
restricted tumor antigen expressed by CT-26, a colon cancer of 
BALB/c mice. BALB/c mice with pre-established subcutaneous 
tumor underwent NST  from MHC-compatible B10.D2 donors. 
Two weeks later, groups of chimeras received nothing, B10.D2 
splenocytes IV, CT-26 tumor vaccine (irradiated CT-26 cells 
mixed with a GM-CSF secreting bystander cell line), or both. By 
staining with H-2L d tetramers loaded with the AHI 423-431 a.a. 
peptide, AHl-specific CD8 + T ceils were found to comprise 2-3% 
of total spleen CD8 + T cells three weeks after vaccination. In con- 
trast~ AHl-specific T cells could not be detected in the non-trans- 
planted, tumor hearing mice. To flirther characterize AHl-specif 
ic T cells we characterized T cell avidity for antigen, as measured 
, by binding ofAH1 peptide-loaded, L ~ IgG dinnners. AH1 specific 
T cells were easily expanded in vitro using AH-1 peptide pulsed 
irradiated BALB/c splenocytes. After four weeks of stimulation 
the highest percentages of cultures containing AHl-specif ic T 
cells were derived from tumor-bearing chimeras that received 
B10.D2 splenocytes and a CT-26 vaccine. Expanded cultures con- 
tained AH-1 specific CD8 + T cells derived front the host and the 
donor, based on the differential expression of Ly9.1 marker on the 
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host lymphocytes and consistent with our recent observations in
short-term cultures (Luznik, L. et al: Blood; in press), interesting- 
ly, M~l-specific allogeneic and host CD8 + T cells, expanded from 
the mixed chimeras had a higher affinity than the T cells derived 
from the vaccinated nontransplanted mice. In conclusion, mixed 
chimerism provides an optimal platform for immunotherapy of 
solid minors not only because of allogeneic effect but also through 
augmentation f host umor-specific immunity. 
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V~ REPERTOIRE ANALYSIS OF TISSUE INFILTRATING CD8+ TCELLS 
RESPONDING TO HINOR HISTOCOHPATIBILITY ANTIGENS 
INVOLVED IN GRAFT-VERSUS-HOST DISEASE 
Friedman, T.}VI.; Castor', D.E.; ffones, S.C.; Komlgold, R. 
KCI/bmmtnology, ffefferson Medical College, Philadelphia, PA. 
Lethal graft versus-host disease (GVHD) can be induced 
between MHC-matched murine strains expressing multiple minor 
histocompatibil ity antigen (miHA) differences. In the B6-> 
BALB.B model, both CD4+ and CDS+ donor can mediate lethal 
GVHD, whereas in the B6->CXBE model (expressing a subset of 
the BALB.B miHA), only the CDS+ T ceils are lethal. CDR3-size 
spectratyping was used to analyze the CD8+ and CD4+ T cell 
responses in both BALB.B and CXBE recipients injected with B6 
CD8+ or CD4+ T cells. Spectratype analysis of the reacting CDS+ 
T ceils indicated overlapping skewing of V]31, 4, 6, 8-10 and 14 
families in both the CXBE and BALB.B recipients and unique 
skewing of the V]3 4 family in the BALB.B recipients. The react- 
ing CD4+ T cells exhibited overlapping expansion of V134, 6-10, 
and 12-14 families, but the B6->BALB.B response also appeared 
to recognize unique BALB.B-specific miHA, indicated by addi- 
tional skewing of V132 and 11. Positively-selected TCR Wo skewed 
CD4+ and CDS+ T cell subsets injected into lethally irradiated 
BALB.B recipients were capable of inducing fatal GVHD. 
BALB.B mice transplanted with non-skewed V]3 CD4+ T cells 
survived with minimal symptoms of GVHD. Here we examine the 
T cell repertoire responses involved in target issue damage. Infil- 
trating B6 host-presensitized CDS+T cells were isolated post- 
transplant from the intestines, livers and spleens of lethally irradi- 
ated CXBE and BALB.B recipients. The results indicated 
overlapping tissue skewing between the B6->BALB.B and B6- 
>CXBE combinations for V]33, 5, 6, 14, and 18 in the spleens, for 
V~5, 9 and 13 in the intestine and V]32 and 18 in the liver. To test 
the possibility that reducing T cell responses within a critical 
GVHD target issue might diminish GVHD lethality we used 
magnetic sorting to remove the intestinal infiltrate skewed V]3 
families from the transplant inoculum. Mice transplanted with 
non-skewed V[3 CDS+ T cells exhibited a two-fold increase in 
median survival time. Taken together these results suggest hat 
differential targeting of T cell responses can be exploited to help 
avoid GVHD. 
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DENDRITIC CELLS CULTURED WITH INTERFERON PLUS GM-CSF CAN 
BE USED TO ELICIT PRI-SPECIFIC CTL FOR ADOPTIVE 
IMMUNOTHERAPY 
Wang, C/; Lu, S/; KJmts, Z.R/: Sukhumalchamlra, P/; Molldrem, 
j.ff.l 1. B3lT/7~ransplant bmmmologL Box 81, M.D. AndersoT~ Cmlcer 
Ceute* , Houstol~, TX; 2.3/1. D. Amterson Crower Center, Houstou, T~. 
We sought a more efficient method to produce potent dendritic 
ceils (DCs) that could be used to elicit PR1-CTL for adoptive 
immunotherapy. Peripheral blood mononuclear cells (PBMC) 
from healthy HLA-A2+ donors were obtained by Ficoll-Hypaque 
separation and monocytes were obtained after two-hour plastic 
adherence. Monocytes were treated for seven days in RPMI medi- 
um plus 10 % human AB serum (HS) with interferon-alpha2b 
(IFN-a) at 1000 units/nil and GM-CSF at 500 units/ml (IF/GM- 
DC). On day seven, the cultures howed a mature phenotype simi- 
lar to DC grown in the same culture media with 1L-4 (1000 
units/ml) and GM-CSF (500 units/ml) (I4/GM-DC): CD83 
(41.9% vs. 39.4%), CDl lc  (90.8% vs.85.23%), CD86, (26.5% vs. 
53.88%) and CD80 (21.9% vs. 35.49%). To compare PRl-specif- 
ic CTL elicited using either DC population, IF/GM-DC and 
IL4/GM-DC were pulsed with PRI at 20 mg/ml, radiated, and 
incubated at a 1:2 ratio with autologous PBMC from HLA-A2+ 
healthy donors. On day 7, 14 and 21 the co-cultures were restimu- 
lated with PR1 pulsed DC, and IL-2 (20 IU/ml) was added the 
following day. PRI -CTL cultures from 6 donors stained with 
PRI/HLA-A2 tetramer showed 0.16% to 5.83% (mean = 1.83%) 
tetramer+ CD8+ lymphocytes from the IF/GM-DC cultures vs. 
0.04% to 7.4% (mean = 1.92%) from the I4/GM-DC cultures 
(p>0.05). IF /GM-DC induced potent PR1-C'I'L proliferation 
with a stimulation index of 2.17 compared with 0.i9 for lympho- 
cytes alone using BrdU incorporation. Mean cytotoxicity results 
from five separate donors showed peptide-specific iysis of 33.8% 
for PRl-coated T2 cells compared with 6.5% for pp65-coated T2, 
at an effector:target ratio of 20:1 by micro-cytotoxicity assay. 
These results how that IFN-a and GM-CSF can be used to elicit 
mature DC cells from PBMC that can be used to elicit PR1-CTL 
after only 21 days of culture. 
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PHASE III TRIAL WITH INFLIXIHAB/HETHYLPREDNISOLONE (HP) VS 
MP FOR THE TREATMENT OF ACUTE GVHD: PRELIMINARY FINDINGS 
Couriel, D.R.; Hicks, K.; Gimlt, S.; Ippoliti, C.; Khouvi, I.; de Lima, 
M.; Homon, E.; Coheir, A.; HosiTzg, C.; Donato, M.; A11derlini, P.; 
Molldrem, tiff.; Gajewski, J.; Champ/in, R. Blood mJd Mar'row Tram- 
pkmtation, UT MD Anderson Cancer Center, Hollstolz, T~\: 
Preclinical and human studies of acute GVHD (aGVHD) suggest 
that tumor necrosis factor-alpha (TNF a) may play an important 
pathogenic role in aGVHD. We have previously reported a high 
response rate in the treatment of steroid-refractory aGVHD with 
infliximab, a chimeric human-monse anti- TNF-a monoclonal anti- 
body. In this study, we vahiate the efficacy and toxicity of inflLximab 
in the upfront reatment of aGVHD. Methods: Single institution, 
open-label, randomized, controlled trial that compares the combina- 
tion of infliximab with MP versus MP in the upfi'ont reatment of 
grade 2 or higher aGVHD. After stratification according to donor 
type and the presence or absence of GI involvement, patients were 
randomized to receive MP (2 mg/kg/day with standardized taper) 
plus infli~mab (10 mg/kg weekly x 4 weeks) or MP alone. Results: 
The trial has currently enrolled 52 patients with an accrual goal of 
100 patients. Of 39 patients evahiable for response, the overall 
response rate of GVHD was 63% (12/19) in the MP + inflLximab arm 
and 50% (10/20) in the MP arm. CR was observed in 11/12 treated 
with MP+ inflixiInab, and all 10 responders in those receiving MP 
alone (p=NS). In the infliximab group responses were observed in 
aGVHD of the skin (n= 10) and the GI tract (n- 5). Fourteen (60%) 
patients in the MP+ inflLximab arm developed one or more bacterial, 
viral or fimgal infections compared to 12 (60%) in the NIP arm (p= 
NS). Median survival was 208 and 168 days for the MP+ infliximab 
and MP groups respectively, and no statistical differences in mortality 
have been observed between the two arms. Number and causes of 
deaths are shown in the Table. Conclusions: So tar, both the MP+ 
inflLximab and MP arms show a similar profile of efficacy, toxicity and 
relapse rate. Both arms have a comparable and relatively high preva- 
lence of infection, highlighting the need for aggressive monitoring 
and prophylaxis nthis population. This study continues accrual. 
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ENGRAFTMENT, GVHD, IMMUNE RECONSTITUTION AND SURVIVAL 
FOLLOWING CDS+ T CELL DEPLETED ALLOGENEIC PERIPHERAL 
BLOOD STEM CELL TRANSPLANTATION (PBSCT) 
Soiff'e'r, R.J.; Alyea, E.P.; Hochbevg, E.; Ho, l'~; Lee, S.; Parileh, B.; 
Fisher, D.; Amil~, ft. Dana Favber CmTce1" hlstimte, Bosto'n, }VIA. 
Partial depletion of CD8+ T cells from donor lymphocyte infu- 
sions reduces the incidence of GVHD without comprmuising 
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